Amanda F. Cashen, MD - Washington ...

Dr. Amanda Cashen, MD

Claim this profile

Washington University School of Medicine

Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
22 reported clinical trials
38 drugs studied

About Amanda Cashen, MD

Education:

  • MD from Washington University School of Medicine, 2015.

Experience:

  • Completed Residency in Internal Medicine at Barnes-Jewish Hospital/Washington University School of Medicine, 2018.
  • Finished Fellowship in Hematology and Oncology at Washington University School of Medicine, 2021.
  • Serving as an Assistant Professor of Medicine at Washington University School of Medicine since 2023.

Affiliated Hospitals

Image of trial facility.
Washington University School Of Medicine
Image of trial facility.
Siteman Cancer Center At West County Hospital

Clinical Trials Amanda Cashen, MD is currently running

Image of trial facility.

Dendritic Cells

for Graft-versus-Host Disease

Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.
Recruiting1 award N/A3 criteria
Image of trial facility.

64Cu-LLP2A Imaging

for Blood Cancers

This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Recruiting1 award Phase < 14 criteria

More about Amanda Cashen, MD

Clinical Trial Related8 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Amanda Cashen, MD has experience with
  • Cytokine Induced Memory-like NK Cell Adoptive Therapy
  • Nivolumab
  • Rituximab
  • Fludarabine
  • Mosunetuzumab
  • Autologous Hematopoietic Stem Cell Transplantation

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Amanda Cashen, MD specialize in?
Is Amanda Cashen, MD currently recruiting for clinical trials?
Are there any treatments that Amanda Cashen, MD has studied deeply?
What is the best way to schedule an appointment with Amanda Cashen, MD?
What is the office address of Amanda Cashen, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security